سعر اماجلوست 4/30مجم 30 قرص 2024

Fixed-dose combination tablets of glimepiride 4 mg and pioglitazone 30 mg, pack of 30 (3 strips), for type 2 diabetes.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and a sulfonylurea or who have inadequate control on either alone (not for type 1 diabetes or diabetic ketoacidosis)Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥5%): upper respiratory tract infection, accidental injury and edema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Initiation in patients with established NYHA Class III or IV heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to pioglitazone, glimepiride or any component; history of allergic reaction to sulfonamide derivatives.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: thiazolidinediones, including pioglitazone, cause or exacerbate congestive heart failure; observe for signs and symptoms of heart failure (rapid weight gain, dyspnea, edema) after initiation and dose increases, and not recommended in symptomatic heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypoglycemia (glimepiride); hypersensitivity reactions including anaphylaxis, angioedema and Stevens-Johnson syndrome; possible increased cardiovascular mortality with sulfonylureas; hepatic effects (hepatic failure reported with pioglitazone); possible bladder cancer risk (do not use in active bladder cancer); edema; increased fractures in females; hemolytic anemia in G6PD deficiency; macular edema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP2C8 inhibitors (e.g., gemfibrozil)Increase pioglitazone exposure about 3-fold; maximum pioglitazone dose is 15 mg daily with these drugs, so patients should switch to the individual components.DailyMed (U.S. National Library of Medicine)
• CYP2C8 inducers (e.g., rifampin)May decrease pioglitazone exposure; adjust based on glycemic response.DailyMed (U.S. National Library of Medicine)
• Oral miconazoleSevere hypoglycemia has been reported with concomitant oral miconazole and glimepiride.DailyMed (U.S. National Library of Medicine)

• Limited data with pioglitazone/glimepiride in pregnant women are insufficient to determine a drug-associated risk; poorly controlled diabetes in pregnancy carries maternal and fetal risks. Neonates of women taking a sulfonylurea at delivery may have prolonged severe hypoglycemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on pioglitazone or glimepiride in human milk; both are present in rat milk. Breastfed infants of mothers on sulfonylureas should be monitored for hypoglycemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Glimepiride: Sulfonylurea that lowers blood glucose mainly by stimulating insulin release from functioning pancreatic beta cells (US label).
• Pioglitazone: Thiazolidinedione that depends on the presence of insulin; decreases insulin resistance in the periphery and liver via PPAR-gamma agonism (US Duetact label).